Agios Pharma (NASDAQ: AGIO) reported Q2 EPS of ($1.69), $0.04 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $44.74 million versus the consensus estimate of $26.57 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.